The majority of Hodgkin lymphoma patients are now cured with conventional first-line therapy; however, 10-15% of early-stage disease and less than 30% of advanced-stage patients are refractory(rare) or relapsed. Salvage second-line therapy combined with high-dose therapy and autologous stem-cell transplantation can cure 40-50% of patients. Recently novel agents (Brentuximab Vedotin and Immune Checkpoint inhibitors) have demonstrated evidence of therapeutic activity and are potential bridge to an allogeneic stem-cell transplantation. The review is aimed to present not only salvage strategies; indeed, the paper contains paragraphs about therapy and new treatment options at diagnosis.

Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors

MUSSETTI, ANDREA;Ricardi, U.;
2018-01-01

Abstract

The majority of Hodgkin lymphoma patients are now cured with conventional first-line therapy; however, 10-15% of early-stage disease and less than 30% of advanced-stage patients are refractory(rare) or relapsed. Salvage second-line therapy combined with high-dose therapy and autologous stem-cell transplantation can cure 40-50% of patients. Recently novel agents (Brentuximab Vedotin and Immune Checkpoint inhibitors) have demonstrated evidence of therapeutic activity and are potential bridge to an allogeneic stem-cell transplantation. The review is aimed to present not only salvage strategies; indeed, the paper contains paragraphs about therapy and new treatment options at diagnosis.
2018
97
8
1301
1315
link.springer.de/link/service/journals/00277/index.htm
Allografting; New salvage treatments; Relapsed/refractory Hodgkin lymphoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Hodgkin Disease; Humans; Immunoconjugates; Immunomodulation; Neoplasm Staging; Positron-Emission Tomography; Retreatment; Salvage Therapy; Treatment Outcome; Vinblastine; Molecular Targeted Therapy; Hematology
Carella, A.M.*; Corradini, P.; Mussetti, A.; Ricardi, U.; Vitolo, U.; Viviani, S.
File in questo prodotto:
File Dimensione Formato  
Treatment of classical Hodgkin lymphoma in the era of brentuximab 2018.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 525.96 kB
Formato Adobe PDF
525.96 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1671007
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact